First National Bank of South Miami Reduces Stock Position in Johnson & Johnson (NYSE:JNJ)

First National Bank of South Miami lowered its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,782 shares of the company’s stock after selling 209 shares during the period. Johnson & Johnson comprises about 0.9% of First National Bank of South Miami’s investment portfolio, making the stock its 23rd biggest holding. First National Bank of South Miami’s holdings in Johnson & Johnson were worth $1,556,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in JNJ. Family CFO Inc purchased a new stake in Johnson & Johnson during the 4th quarter valued at $26,000. Steward Financial Group LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $34,000. Jackson Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock worth $40,000 after purchasing an additional 277 shares during the period. Advocacy Wealth Management Services LLC lifted its position in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after purchasing an additional 67 shares during the period. Finally, Iron Horse Wealth Management LLC lifted its position in shares of Johnson & Johnson by 29.9% in the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares during the period. 68.78% of the stock is owned by institutional investors and hedge funds.

JNJ stock opened at $175.74 on Thursday. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company’s fifty day moving average price is $177.66 and its 200-day moving average price is $173.09. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The company has a market capitalization of $462.44 billion, a PE ratio of 23.68, a price-to-earnings-growth ratio of 3.35 and a beta of 0.66.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, topping the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The firm had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. During the same quarter in the previous year, the firm earned $2.59 earnings per share. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, research analysts predict that Johnson & Johnson will post 10.23 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were paid a dividend of $1.13 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date of this dividend was Monday, May 23rd. This represents a $4.52 dividend on an annualized basis and a yield of 2.57%. Johnson & Johnson’s dividend payout ratio is presently 60.92%.

In related news, insider William Hait sold 29,699 shares of the company’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 78,161 shares of company stock worth $13,895,302. 0.35% of the stock is owned by insiders.

Several equities research analysts have recently commented on JNJ shares. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research report on Wednesday. They set an “outperform” rating for the company. The Goldman Sachs Group raised their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $190.50.

Johnson & Johnson Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.